Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYuting YanXZXinyi ZhangTWTingyu Wang

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates genomic mutations enhance prognostic assessment in patients with Waldenström macroglobulinemia receiving BTK inhibitors.

Key Points

  • Assess the prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia (WM) before and after the introduction of BTK inhibitors.
  • Retrospective analysis of patients with symptomatic WM diagnosed between June 2013 and June 2023
  • Evaluation of MYD88 and CXCR4 mutations using Sanger sequencing and targeted next-generation sequencing
  • Comparison of prognostic models (IPSSWM, rIPSSWM, MSSWM) for overall survival in patients receiving BTK inhibitors versus non-BTK therapies.
  • rIPSSWM model shows the highest predictive accuracy for overall survival in the non-BTKi cohort (C-statistic: 0.702)
  • MYD88 mutation linked to favorable outcomes in first-line BTK-based therapy
  • CxCR4 mutation associated with inferior prognosis in both treatment cohorts
  • Traditional clinical models less reliable in the BTKi era, emphasizing need for genetic profiling in risk assessment

Cite This Study

Yan et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236d9edhttps://doi.org/10.1182/blood-2025-3593
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data2025
  2. 2P73 | TP53 MUTATION AND MSS-WM IDENTIFY HIGH RISK WALDENSTROM MACROGLOBULINEMIA IN A REAL WORLD COHORT2026
  3. 3Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia2025
  4. 4Genetic evolution of Waldenström macroglobulinemia across disease stages2025
  5. 5Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre2026 · 1 citations